Home > Maligne hematologie > Myeloïde ziekten > Myelodysplastisch syndroom > SAR443579 – TCD17197

Printen

Versie:	1.0.0
Revisie:	30-09-2022
Type:	Studie
Status:	Tijdelijk gesloten
Ziektebeeld:	Myelodysplastisch syndroom, Acute lymfatische leukemie (ALL) en lymfoblastair lymfoom (LBL), AML (incl. APL)
Behandellijn:	>= 2de lijn
Fase:	Fase 2, Fase 1
Leeftijd:	≥ 18
PI:	Prof. Dr. G.A. Huls
TC:	Sanne van der Kooi
Titel:	An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high riskmyelodysplasia (HR-MDS)

SAR443579 – TCD17197

Studieprotocol

SAR443579 – TCD17197 Protocol

ICF

Sar443579 - TCD17191 ICF

An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high riskmyelodysplasia (HR-MDS)

SAR443579 – TCD17197

Hematologie Groningen